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Effects of pcv2 vaccine on the growth performance of pigs and mortality rate in a
pcv2-positive commercial swine herd
Abstract
A total of 1,470 pigs were used to study a commercial sow herd with a history of Porcine Circovirus
Disease (PCVD). The objective was to evaluate the effect of two commercially available Porcine
Circovirus Type 2 (PCV2) vaccines on growth and mortality rates. The first vaccine was administered one
week after weaning (1-dose) while the second was administered at weaning and repeated three weeks
later (2-dose). A third group of unvaccinated pigs served as a control group. Pigs were individually
weighed at weaning (d 0), d 113, 143, and just prior to market. On d 113, pigs on the 2-dose treatment
were heavier (P<0.05) than the control group, and the 1-dose treatment pigs were intermediate. At d 143,
just prior to when the first pigs were marketed, both the 1-dose and the 2-dose pigs were heavier than the
control pigs by 7.6 and 10.2 lb (P<0.05), respectively, and there were no significant differences in weights
between the two vaccinated groups. However, differences in weights between the vaccinated and the
control pigs were smaller at off-test compared to differences at d 143 due to a wider variability in on-test
days as a result of multiple marketing days prior to end of the trial. Although there were no significant
differences between the two vaccinated groups, ADG was greater (P<0.05) in all vaccinated pigs
compared to non-vaccinated control pigs from d 0 to d 113, d 143, and at off-test. From d 113 to 143 and
until the day they were taken off test, there were no differences in ADG, regardless of treatment. This
suggests that the increase in growth rate in vaccinated pigs occurred during the period d 0 to 113.
Barrows consistently exhibited greater ADG and heavier weights (P<0.05) than gilts throughout the trial.
No significant differences in mortality rate between treatments were observed but both vaccinated
groups had mortality rates that were 3% lower than the non-vaccinated control pigs. Based on these
results, both commercial vaccines were effective in mitigating the effects of PCV2 virus and improving
the growth performance of pigs in a PCV2 positive herd.; Swine Day, 2007, Kansas State University,
Manhattan, KS, 2007
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EFFECTS OF PCV2 VACCINE ON THE GROWTH PERFORMANCE OF PIGS AND
MORTALITY RATE IN A PCV2-POSITIVE COMMERCIAL SWINE HERD
J. Y. Jacela1, S. S. Dritz1, M. D. Tokach, J. M. DeRouchey, R. D. Goodband,
J. L. Nelssen, R. C. Sulabo, and J. R. Bergstrom

to d 113, d 143, and at off-test. From d 113 to
143 and until the day they were taken off test,
there were no differences in ADG, regardless
of treatment. This suggests that the increase in
growth rate in vaccinated pigs occurred during
the period d 0 to 113. Barrows consistently
exhibited greater ADG and heavier weights
(P<0.05) than gilts throughout the trial. No
significant differences in mortality rate between treatments were observed but both vaccinated groups had mortality rates that were
3% lower than the non-vaccinated control
pigs. Based on these results, both commercial
vaccines were effective in mitigating the effects of PCV2 virus and improving the growth
performance of pigs in a PCV2 positive herd.

Summary
A total of 1,470 pigs were used to study a
commercial sow herd with a history of Porcine
Circovirus Disease (PCVD). The objective
was to evaluate the effect of two commercially
available Porcine Circovirus Type 2 (PCV2)
vaccines on growth and mortality rates. The
first vaccine was administered one week after
weaning (1-dose) while the second was administered at weaning and repeated three
weeks later (2-dose). A third group of unvaccinated pigs served as a control group. Pigs
were individually weighed at weaning (d 0), d
113, 143, and just prior to market. On d 113,
pigs on the 2-dose treatment were heavier
(P<0.05) than the control group, and the 1dose treatment pigs were intermediate. At d
143, just prior to when the first pigs were
marketed, both the 1-dose and the 2-dose pigs
were heavier than the control pigs by 7.6 and
10.2 lb (P<0.05), respectively, and there were
no significant differences in weights between
the two vaccinated groups. However, differences in weights between the vaccinated and
the control pigs were smaller at off-test compared to differences at d 143 due to a wider
variability in on-test days as a result of multiple marketing days prior to end of the trial.
Although there were no significant differences
between the two vaccinated groups, ADG was
greater (P<0.05) in all vaccinated pigs compared to non-vaccinated control pigs from d 0

(Key words: health, PCVAD, PCV2.)
Introduction
Porcine Circovirus Diseases (PCVD) is
considered a disease of major economic importance because of its ability to cause high
death loss and poor growth performance. The
disease is caused by Porcine Circovirus Type
2 (PCV2) and the condition is usually nonresponsive to antibiotic treatment due to the
viral cause. Clinical signs of the disease include poor body condition with varying degrees of muscle wasting, labored breathing,
and enlarged lymph nodes. Death loss can be
as high as 40% in severely affected herds. The

1

Food Animal Health and Management Center, College of Veterinary Medicine.

5

ery rooms and were then transferred to opensided, naturally ventilated buildings during the
growing to finishing phase. All on-test pigs
were weighed on days 0, 113, and 143 and just
prior to market to determine average daily
gain. Weighing of pigs just prior to market
was done in several batches for each group as
part of the topping-out procedure of the farm.
Thus, heavier pigs were weighed earlier than
the rest of the pigs if they already weighed at
least 270 lb before the scheduled weigh date
for each block. Average daily gain was analyzed from only those pigs that were marketed. Only weight gains of pigs marketed
were used for the calculation of ADG and
weight gains of dead pigs were not used in the
calculation for ADG.

PCV2 virus is very stable and resistant to inactivation. Preventing or minimizing the
chances of infection requires exceptionally
good husbandry practices. Although researchers have confirmed PCV2 as the main infectious agent to trigger the disease, PCVD may
require other factors or agents for clinical
signs and lesions to appear. Positive responses
and initial field results with the use of recently
developed vaccines have further confirmed the
major role PCV2 plays in the development of
the disease. These results have been very
promising; however, most of these were reported in terms of mortality reduction and
very little study has been done with the vaccine in terms of growth performance. Therefore, the objective of this trial was to compare
the effects of two commercially available
PCV2 vaccines (1- or 2-dose) on growth rate
and mortality.

On-test pigs that died were recorded and
mortality rate was calculated as number of
deaths divided by the initial number of pigs
placed on test. A total of 15 pigs (5 nursery
and 10 finishing) with clinical signs indicative
of PCVD were submitted to the KSU Diagnostic Laboratory for necropsy and histopathological examination to confirm the presence of PCV2 infection.

Procedures
The experiment was conducted in a 2,000sow commercial farm in Northeastern Kansas
with a history of PCVD. A total of 1,470
weaned pigs (825 barrows and 645 gilts) were
ear-tagged for identification and randomly allotted to one of three treatments with gilts and
barrows equally allocated to each treatment
group. Pigs were placed on test from three different weaning groups and weaning group was
considered a block. All pigs were free of any
physical defect and in good body condition.
The treatments included a negative control
(non-vaccinated), 1-dose-vaccinated, and 2dose vaccinated pigs. The 1-dose pigs were
vaccinated one week after weaning while 2dose pigs were vaccinated at weaning and repeated three weeks later. The vaccines were
commercially available (1-dose: Fort Dodge,
2-dose: Intervet) and administered according
to label instructions.

Data were analyzed as a 3 × 2 factorial
randomized complete block design using the
MIXED procedure of SAS. The fixed effects
were vaccine treatment (control, 1-dose, and
2-dose) and sex (barrow or gilt) with the random effect of wean group.
Results and Discussion
Histopathologic lesions associated with
PCV2 infection were noted in pigs necropsied
from each of the three weaning groups. Average weight of pigs given the 2-dose vaccine
was greater (P<0.05) than the control pigs at
mid-finishing (d 113 on-test) but not different
from pigs that were given the 1-dose vaccine,
which were intermediate. At day 143 on-test,
no significant difference in average pig weight

Each weaning group was initially housed
in three separate mechanically ventilated nurs-
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between the vaccinated groups and control
group at d 113 and 143 on-test. All groups did
not exhibit any significant difference in ADG
from Day 113 to Day 143 and at off-test,
which indicates that significant difference in
growth rates occurs between d 0 and 113.

was observed between the two vaccinated
groups. However, the 1-dose vaccinated and
2-dose vaccinated groups were heavier by 7.6
and 10.2 lb (P<0.05), respectively, than the
control groups. This is demonstrated by the
greater number of pigs weighing 260 lb or
more in the vaccinated groups compared to the
control group at d 143 (Figure 1). Pigs on the
2-dose treatment had heavier (P<0.05) off-test
weights than did non-vaccinated pigs, and 1dose treated pigs were intermediate. However,
weight differences between the vaccinated
groups and the control group was noticeably
smaller at off-test compared to differences at d
143. This may be explained by the fact that all
groups were topped out several days before
they were taken off test leaving the rest of the
pigs within close weight range across all
groups.

No differences in mortality rate were
noted between any of the treatment groups.
However, the two vaccinated groups had 3%
lower mortality compared to the control group
(7.7 and 7.8% vs. 11.0%, respectively). We
believe that the absence of statistical difference among the treatments is due to the
greater variability as a result of a respiratory
disease outbreak during the trial. A clinical
outbreak of bacterial disease due to Haemophilus parasuis was noted in two nursery
groups. Additionally, an outbreak of respiratory disease due to Actinobacillus pleuropneumoniae was noted in one finisher
group.

Also, the control group was on test longer
compared to the two groups, which allowed
them to gain more weight and close the weight
gap. There were no sex by treatment interactions observed, but as expected, barrows were
significantly heavier (P<0.05) than gilts on d
113 up to market.

In conclusion, both commercial PCV2
vaccines were effective in improving the
growth performance of pigs from weaning to
finishing as shown by heavier weights and
greater ADG of the vaccinated groups. There
were no statistically significant differences
between the two vaccines in terms of the parameters measured. However, pigs given the
2-dose vaccine were 2.6 lb heavier than those
given the 1-dose vaccine at d 143 after weaning.

There was no significant difference in
ADG among the pigs from the 1-dose and 2dose vaccinated groups from d 0 to 113, 143,
or off-test. However, on all occasions both
vaccinated groups exhibited greater ADG
(P<0.05) compared to the control group. This
explains the widening gap in average weights
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Table 1. Effects of PCV2 Vaccine on Growth Performance and Mortality Rate1
Item
Weight, lb
D0
D 113
D 143
Off-test

Vaccine Main Effect
Control
1-dose2
2-dose3

Sex Main Effect
Barrows
Gilts

P-values
Vaccine
Sex

19.1
181.8a
237.3a
256.7 a

19.6
188.2ab
244.8b
261.8 ab

19.3
190.7b
247.4b
265.0 b

19.3
190.3
248.7
265.3

19.4
183.5
237.6
257.1

0.24
0.04
0.03
0.05

0.50
<0.0001
<0.0001
<0.0001

Days On-test

153.2

151.8

151.9

151.2

153.3

0.08

<0.0001

ADG, lb
D 0 to 113
D 0 to 143
D 0 to Market
D 113 to D 143
D113 to Market

1.44a
1.53a
1.55a
1.89
1.89

1.49b
1.58b
1.60b
1.91
1.93

1.52b
1.60b
1.62b
1.94
1.95

1.51
1.61
1.63
2.00
2.00

1.45
1.53
1.55
1.84
1.84

0.02
0.02
0.02
0.39
0.25

<0.0001
<0.0001
<0.0001
<0.0001
<0.0001

Mortality, %
11.0
7.8
7.7
8.7
9.0
0.42
0.86
a,,b
Means within the vaccine main effect lacking a common superscript differ P<0.05.
1
A total of 1,470 pigs were randomly assigned at weaning (d 0) to one of the three vaccine treatments
within barrows and gilts.
2
1-dose was the PCV2 vaccine available from Fort Dodge administered one week after weaning .
3
2-dose was the commercially available vaccine from Intervet administered at weaning and 3 weeks
later.
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Effect of PCV2 Vaccine on Average Weight
(Day 143 On-test)
30.0
Control

Frequency

25.0

1-dose

20.0

2-dose

15.0
10.0
5.0
0.0
<140

160

180

200

220

240

260

280

300

320

Weight, lb
Figure 1. Comparative Weight Distribution of Treatment Groups at Day 143 on-Test.
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